Revumenib and Methadone: Two QT-Prolonging Drugs, One Leukemia
His relapsed AML carries the exact rearrangement revumenib was built for. He's also stable on methadone for opioid use disorder — another drug that lengthens the QT interval. Neither problem should be solved by ignoring the other.
Six years ago Tyler B. was, by his own description, not someone anyone expected to still be around at 29. He has been stable on methadone maintenance for opioid use disorder that entire time, without a documented relapse — a stretch his outpatient addiction medicine team describes as genuinely hard-won, built on a job he's held for four years operating a forklift at a regional distribution warehouse and a routine he protects carefully. He was diagnosed with AML eight months ago, achieved an initial remission with intensive induction, and has now relapsed, with disease confirmed by cytogenetics to carry a KMT2A rearrangement.
That molecular finding specifically defines eligibility for revumenib, a menin inhibitor built to disrupt the menin-KMT2A interaction these leukemias depend on, and relapsed KMT2A-rearranged AML has few other effective options remaining. The complication sitting underneath the molecular match, though, is pharmacologic rather than oncologic: methadone is itself a well-documented, dose-dependent QT-prolonging drug, and revumenib's own label carries QT prolongation as a warning and directs prescribers to avoid concomitant QTc-prolonging drugs outright, monitoring more frequently only where the combination is unavoidable. That is the situation here: the combination is unavoidable, so the label's fallback is the actual standard he has to be held to, not a caution to be noted and moved past.
His baseline ECG today shows a QTc of 438 milliseconds — within normal range but not far from it, on his stable methadone dose alone, before either the leukemia's own metabolic stress or a second QT-prolonging drug enters the picture. A second, quieter layer sits underneath the QT question: revumenib is a CYP3A4 substrate, so the interaction that actually matters runs toward revumenib rather than away from it — a strong CYP3A4 inhibitor raises revumenib exposure two- to two-and-a-half-fold and requires a label-directed dose reduction, while an inducer lowers it and raises the M1 metabolite that itself prolongs QT. Methadone is not a strong CYP3A4 inhibitor and is not expected to do either, but his full medication list needs a pharmacy interaction review before the first dose regardless of which position on the QT question wins.
Whatever the team decides about revumenib, his addiction medicine team has already asked to be part of the conversation, not informed after the fact — six years of stability is not something anyone here wants to treat as incidental to the leukemia plan, and Tyler himself has said plainly that keeping his methadone unchanged matters to him as much as any answer about the leukemia itself.
Two QT-prolonging drugs, one decision
Start revumenib. Relapsed KMT2A-rearranged AML has very few effective options left, and AUGMENT-101 showed real, meaningful responses — roughly a quarter of heavily pretreated patients achieving CR or CRh — in exactly this population. That's not a window we should let close while working through a manageable drug interaction.
I'm not arguing against revumenib. I'm arguing that methadone's QT-prolongation isn't a footnote — it's dose-dependent, well-documented, and his baseline QTc is already 438 on methadone alone. Revumenib's label says to avoid a concomitant QT-prolonging drug altogether, and it holds the drug at a QTc above 480 — he starts 42 milliseconds under that line, not the 62 he'd have under the 500 figure people default to. Stacking a second QT-prolonging agent onto a patient who's clinically unstable from active leukemia is real torsades risk, not a theoretical caveat.
My first instinct is to switch him to buprenorphine, which doesn't carry methadone's QT liability, before starting revumenib.
The interaction is real — I want to be clear I'm not disputing that.
But switching a patient six years stable on methadone during an active leukemia crisis carries its own documented harm: precipitated withdrawal, or relapse to illicit use, at exactly the moment he can least absorb another destabilizing event. The actual risk isn't uniform across his whole treatment course — it concentrates in the first two weeks, during revumenib dose titration and any differentiation response, which is when QT effects are most likely to compound. Continue methadone at his current stable dose, get a baseline QTc today, then daily ECGs through that early window with magnesium and potassium repletion on hand, holding revumenib if QTc crosses 480 — which is revumenib's own labeled hold threshold, not the generic 500-millisecond figure people reach for, and the label is explicit that it resumes only once QTc is back at 480 or below. That solves the actual risk without creating a second crisis to manage the first one.
Agreed: continue methadone at his current dose rather than switch it; start revumenib with baseline QTc and daily ECGs through the first two weeks of titration, magnesium and potassium kept repleted, with a pre-specified threshold taken from revumenib's own label rather than a general rule of thumb (hold for QTc above 480 ms, resume at 480 or below). His outpatient addiction medicine team was looped in directly rather than the decision being made without them.
Not agreed: whether future revumenib maintenance dosing after transplant should be timed around a planned, elective methadone taper once he's clinically stable, or whether that conversation should wait entirely until transplant timing is clearer. Left open, to be revisited with his addiction medicine team once a transplant date exists.